# Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy

Study · id `cardio:ct-nct03832660` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03832660](<https://clinicaltrials.gov/study/NCT03832660>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03832660

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.

## Technical summary

Registry record NCT03832660. Randomized; no masking; primary purpose treatment. Start 2019-05-03 (actual); primary completion 2022-05-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 168 participants (enrolled count; ClinicalTrials.gov record NCT03832660, source copy `cardio:ctgov-nct03832660-2022-11-28`, retrieved 2026-10-31)
- Started: 2019-05-03 (actual) (ClinicalTrials.gov record NCT03832660, source copy `cardio:ctgov-nct03832660-2022-11-28`, retrieved 2026-10-31)
- Primary completion: 2022-05-15 (actual) (ClinicalTrials.gov record NCT03832660, source copy `cardio:ctgov-nct03832660-2022-11-28`, retrieved 2026-10-31)
- Completion: 2022-06-30 (actual) (ClinicalTrials.gov record NCT03832660, source copy `cardio:ctgov-nct03832660-2022-11-28`, retrieved 2026-10-31)
- Countries: Germany; Italy; Serbia; United Kingdom (ClinicalTrials.gov record NCT03832660, source copy `cardio:ctgov-nct03832660-2022-11-28`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03832660-2022-11-28`, retrieved 2026-10-31)

## The registry's words

- Brief title: Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy
- Acronym: SILICOFCM
- Condition: Hypertrophic Cardiomyopathy
- Intervention (Behavioral): Lifestyle
- Intervention (Drug): Sacubitril/Valsartan
- Lead sponsor: Newcastle University
- Lead sponsor class: OTHER
- Collaborator: Azienda Ospedaliero-Universitaria Careggi
- Collaborator class: OTHER
- Collaborator: University Hospital Regensburg
- Collaborator class: OTHER
- Collaborator: Institute of Cardiovascular Diseases, Vojvodina
- Collaborator class: OTHER
- Collaborator: University of Belgrade
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Newcastle University (`cardio:org-newcastle-university`)
- Registry lists this organization as a collaborator: Azienda Ospedaliero-Universitaria Careggi (`cardio:org-azienda-ospedaliero-universitaria-careggi`)
- Registry lists this organization as a collaborator: Institute of Cardiovascular Diseases, Vojvodina (`cardio:org-institute-of-cardiovascular-diseases-vojvodina`)

## Provenance

Content hash: 2cf336780071b948bf774c63292749a2004f4f7524308306abee972197c59e5d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
